Consensus Report on Shigella Controlled Human Infection Model: Introduction and Overview

Clin Infect Dis. 2019 Dec 9;69(Suppl 8):S577-S579. doi: 10.1093/cid/ciz886.

Abstract

In recent years, controlled human infection models (CHIMs) have become available for a range of infectious agents and have proved invaluable for understanding the disease process, pathogenesis, and mechanisms of immunity. CHIM studies have also contributed significantly to advancing development of a number of vaccines by providing an indication of vaccine efficacy. The Shigella CHIM has been established in 3 sites in the United States, and it is likely that the CHIM will play an important regulatory role for advancing the range of Shigella vaccine candidates that are currently in development. This supplement describes the harmonization of best practices across sites, with a view to maximizing the contribution that CHIM studies can make to Shigella vaccine development.

Keywords: Shigella; controlled human infection model; human infection studies.

Publication types

  • Introductory Journal Article

MeSH terms

  • Clinical Trials as Topic / standards*
  • Consensus Development Conferences as Topic
  • Consensus*
  • Drug Development / standards
  • Dysentery, Bacillary / prevention & control*
  • Humans
  • Models, Biological*
  • Research Report
  • Shigella / immunology
  • Shigella Vaccines / immunology
  • Shigella Vaccines / standards*
  • United States

Substances

  • Shigella Vaccines